Fidelity Investments’s TransCode Therapeutics RNAZ Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAZ
Fidelity Investments's RNAZ Position: Q3 2026 in Review
Fidelity Investments reduced its TransCode Therapeutics (RNAZ) stake by 98% in Q3 2026, selling an estimated $2.89K and leaving 11 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #5690.
Fidelity Investments first reported a position in RNAZ in Q1 2025 and has held it in 4 quarters since. The position peaked at $4.38K in Q2 2026. 12 funds tracked by Wall St. Rank hold RNAZ as of Q3 2026.
- Fidelity Investments held 11 shares of TransCode Therapeutics worth $18 as of Q3 2026.
- Fidelity Investments sold 695 TransCode Therapeutics shares in Q3 2026, an estimated $2.89K.
- TransCode Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5690 holding.
- Fidelity Investments first reported a position in TransCode Therapeutics in Q1 2025 and has held it in 4 quarters since.
- Fidelity Investments's TransCode Therapeutics position peaked at $4.38K in Q2 2026.
- 12 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.